Relative to promoting healthcare access and affordability for patients
Impact
The bill seeks to repeal several sections of previous acts to eliminate certain outdated regulations. A key component of the proposed changes is the introduction of a new section in Chapter 176O of the General Laws, which mandates that health insurers pass on a minimum of 80% of estimated rebates received from pharmaceutical companies to the insured, rather than retaining these rebates. This obligation is designed to reduce out-of-pocket costs for patients at the point of sale, effectively improving affordability in medication costs. To ensure compliance, the bill sets forth a structure for fines against insurance companies that fail to adhere to these new regulations.
Summary
House Bill H1364, titled 'An Act relative to promoting healthcare access and affordability for patients', aims to enhance access to healthcare services while simultaneously making them more affordable. The bill, filed by Representative Carole A. Fiola, outlines a series of provisions intended to modify existing regulations governing health insurers, specifically in how they operate regarding prescription medication and healthcare services. This includes changes to the responsibilities of pharmacy benefit managers (PBMs), which are intermediaries between insurers and pharmacies, particularly in relation to price negotiations and rebate disclosures.
Contention
One point of contention regarding H1364 centers around transparency in pricing for prescription drugs and the role of PBMs. While proponents argue that ensuring a larger share of rebates reach consumers will promote fairness and lower costs, critics express concerns about the practicality of enforcing these provisions and the potential for PBMs to retaliate against insurers that comply. Furthermore, there may be concerns regarding how changes in regulatory frameworks could impact the availability of innovative treatments, particularly in the fields of gene and cell therapies, as a section of the bill mandates a comprehensive analysis of barriers to access associated with these therapies for patients under state programs like MassHealth.